دورية أكاديمية
أعرض في EDS

The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.

التفاصيل البيبلوغرافية
العنوان: The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.
المؤلفون: Kujawski SA; Center for Observational and Real-World Evidence (CORE), Merck & Co. Inc, Rahway, NJ, USA., Burgess C; Biostatistics and Research Decision Sciences - Health Economic Decision Sciences (BARDS-HEDS), Merck & Co. Inc, Rahway, NJ, USA., Agi O; Market Access and External Affairs, MSD, Hod HaSharon, Israel., Attias-Geva Z; Medical Affairs, Vaccines, MSD, Hod HaSharon, Israel., Pillsbury M; Biostatistics and Research Decision Sciences - Health Economic Decision Sciences (BARDS-HEDS), Merck & Co. Inc, Rahway, NJ, USA., Greenberg D; Pediatric Infectious Disease Unit, Ben Gurion University of the Negev, Beer-Sheva, Israel., Bencina G; Center for Observational and Real-World Evidence (CORE), MSD, Madrid, Spain., Pawaskar M; Center for Observational and Real-World Evidence (CORE), Merck & Co. Inc, Rahway, NJ, USA.
المصدر: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2124784. Date of Electronic Publication: 2022 Oct 31.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
مواضيع طبية MeSH: Measles-Mumps-Rubella Vaccine* , Chickenpox*/epidemiology , Chickenpox*/prevention & control, Humans ; Infant ; Chickenpox Vaccine ; Herpesvirus 3, Human ; Vaccines, Combined
مستخلص: Currently available health economic models for varicella infection are designed to inform the cost-effectiveness of universal varicella vaccination (UVV) compared with no vaccination. However, in countries with an existing UVV program, these models cannot be used to evaluate whether to continue with the current varicella vaccine or to switch to an alternative vaccine. We developed a dynamic transmission model that incorporates the historical vaccination program to project the health and economic impact of changing vaccination strategies. We applied the model to Israel, which initiated UVV in 2008 with a quadrivalent vaccine, MMRV-GSK, and switched to MMRV-MSD in 2016. The model was calibrated to pre-vaccination incidence data before projecting the impact of the historical and future alternative vaccination strategies on the clinical burden of varicella. Total costs and QALYs lost due to varicella infections were projected to compare continuing with MMRV-MSD versus switching to MMRV-GSK in 2022. Over a 50-year time horizon, continuing with MMRV-MSD reduced varicella incidence further by 64%, reaching 35 cases per 100,000 population by 2072, versus a 136% increase in incidence with MMRV-GSK. Continuing with MMRV-MSD reduced cumulative hospitalization and outpatient cases by 48% and 58% (vs. increase of 137% and 91% with MMRV-GSK), respectively. Continuing with MMRV-MSD resulted in 139 fewer QALYs lost with total cost savings of 3% compared with switching to MMRV-GSK, from the societal perspective. In Israel, maintaining the UVV strategy with MMRV-MSD versus switching to MMRV-GSK is projected to further reduce the burden of varicella and cost less from the societal perspective.
References: Isr J Health Policy Res. 2021 Jan 26;10(1):7. (PMID: 33499907)
Pediatrics. 1976 Nov;58(5):692-6. (PMID: 185578)
Pediatrics. 2016 Mar;137(3):e20153741. (PMID: 26908671)
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697. (PMID: 28898249)
Hum Vaccin Immunother. 2015;11(1):63-71. (PMID: 25483517)
Pediatrics. 1993 Dec;92(6):833-7. (PMID: 8233746)
Pediatr Infect Dis J. 2019 Feb;38(2):181-188. (PMID: 30408002)
BMJ. 2020 Jan 22;368:l6987. (PMID: 31969318)
Pediatr Infect Dis J. 2004 Feb;23(2):132-7. (PMID: 14872179)
Pediatr Infect Dis J. 2021 Jun 1;40(6):e217-e221. (PMID: 33872276)
Epidemiol Infect. 2000 Dec;125(3):651-69. (PMID: 11218215)
J Infect. 2004 Feb;48(2):119-33. (PMID: 14720487)
Vaccine. 2014 Jan 3;32(2):277-83. (PMID: 24275483)
Infection. 2006 Aug;34(4):208-13. (PMID: 16896579)
PLoS One. 2013 Apr 17;8(4):e60732. (PMID: 23613740)
J Infect. 2013 Nov;67(5):463-9. (PMID: 23872209)
Lancet. 2006 Oct 14;368(9544):1365-76. (PMID: 17046469)
Clinicoecon Outcomes Res. 2020 Jun 08;12:273-283. (PMID: 32606844)
Clin Infect Dis. 2021 Dec 6;73(11):e3617-e3626. (PMID: 33173938)
Pediatr Infect Dis J. 2012 Dec;31(12):1263-8. (PMID: 23188098)
Vaccine. 2002 Jun 7;20(19-20):2500-7. (PMID: 12057605)
Clin Ther. 2015 Apr 1;37(4):830-841.e7. (PMID: 25721380)
Lancet Infect Dis. 2019 Mar;19(3):287-297. (PMID: 30765242)
JAMA. 1997 Nov 12;278(18):1495-9. (PMID: 9363968)
Neurology. 2013 Sep 3;81(10):928-30. (PMID: 23999562)
PLoS One. 2021 Jul 8;16(7):e0254080. (PMID: 34237090)
N Engl J Med. 2005 Feb 3;352(5):450-8. (PMID: 15689583)
Epidemiol Infect. 2009 Jan;137(1):38-47. (PMID: 18466661)
Pediatrics. 2013 May;131(5):e1389-96. (PMID: 23545380)
Bull Math Biol. 1999 Nov;61(6):1031-64. (PMID: 17879870)
Clin Vaccine Immunol. 2014 May;21(5):762-8. (PMID: 24671555)
Vaccine. 2022 Jun 23;40(29):3954-3962. (PMID: 35660037)
PLoS One. 2019 Aug 13;14(8):e0220921. (PMID: 31408505)
Hum Vaccin Immunother. 2019;15(3):645-657. (PMID: 30427766)
BMC Infect Dis. 2017 May 18;17(1):353. (PMID: 28521810)
Vaccine. 2011 Mar 16;29(13):2411-20. (PMID: 21277405)
JAMA. 2004 Aug 11;292(6):704-8. (PMID: 15304467)
Epidemiol Infect. 1992 Jun;108(3):495-511. (PMID: 1318218)
Wkly Epidemiol Rec. 2014 Jun 20;89(25):265-87. (PMID: 24983077)
BMC Infect Dis. 2010 Aug 03;10:230. (PMID: 20682044)
فهرسة مساهمة: Keywords: Varicella; cost-effectiveness; dynamic transmission model; varicella vaccination
المشرفين على المادة: 0 (Measles-Mumps-Rubella Vaccine)
0 (Chickenpox Vaccine)
0 (Vaccines, Combined)
تواريخ الأحداث: Date Created: 20221031 Date Completed: 20221216 Latest Revision: 20230112
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9746549
DOI: 10.1080/21645515.2022.2124784
PMID: 36315970
قاعدة البيانات: MEDLINE
الوصف
تدمد:2164-554X
DOI:10.1080/21645515.2022.2124784